Beam Therapeutics Inc. (BEAM) — Financial statements
Income statement, balance sheet, and cash flow for Beam Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 140↑120.0% | 64↓83.2% | 378↑520.0% | 61↑17.5% | 52 | |
| Cost of Revenue | 22↓93.9% | 368 | 0.00↓100.0% | 312↑34.2% | 232 | |
| Gross Profit | 117↑138.6% | -304↓180.5% | 378↑250.7% | -251↓39.0% | -180 | |
| Operating Expenses | ||||||
| R&D Expenses | 410↑11.4% | 368↓16.0% | 437↑40.4% | 312↓19.5% | 387 | |
| General & Administrative Expenses | 114↑2.1% | 112↓4.5% | 117↑33.0% | 88↑53.4% | 57 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 114↑2.1% | 112↓4.5% | 117↑33.0% | 88↑53.4% | 57 | |
| Other Expenses | -22↑93.9% | -368 | 0.00↑100.0% | -312↓34.2% | -232 | |
| Operating Expenses | 501↑349.4% | 112↓79.9% | 554↑531.2% | 88↓58.6% | 212 | |
| Total Costs & Expenses | 523↑9.3% | 479↓13.6% | 554↑38.8% | 399↓10.1% | 444 | |
| Operating Results | ||||||
| Operating Income | -384↑7.7% | -416↓135.5% | -176↑47.9% | -338↑13.8% | -392 | |
| Depreciation & Amortization | 6↓71.1% | 22↓25.8% | 30↑108.7% | 14↑89.9% | 7 | |
| EBITDA | -30↑92.4% | -394↓167.9% | -147↑54.7% | -324↓41.0% | -230 | |
| EBIT | -36↑91.3% | -416↓135.5% | -176↑47.9% | -338↓42.5% | -238 | |
| Interest & Other Income | ||||||
| Net Interest Income | -44↓189.1% | 49 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00↓100.0% | 49 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 44 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -347 | 0.00 | 0.00 | 0.00↑100.0% | -155 | |
| Other Income / Expenses | 304↑681.4% | 39↓14.3% | 45↓14.2% | 53↑141.9% | 22 | |
| Income Before Tax | -80↑78.8% | -377↓187.2% | -131↑54.1% | -286↑22.9% | -371 | |
| Income Tax Expense | 0.00↓100.0% | 0.04↓97.1% | 1↓59.9% | 3 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -80↑78.8% | -377↓184.3% | -133↑54.2% | -289↑22.0% | -371 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -80↑78.8% | -377↓184.3% | -133↑54.2% | -289↑22.0% | -371 | |
| Bottom-Line Net Income | -80↑78.8% | -377↓184.3% | -133↑54.2% | -289↑22.0% | -371 | |
| EPS (Basic) | -0.81↑82.3% | -4.58↓166.3% | -1.72↑58.4% | -4.13↑28.4% | -5.77 | |
| EPS (Diluted) | -0.81↑82.3% | -4.58↓166.3% | -1.72↑58.4% | -4.13↑28.4% | -5.77 | |
| Weighted Average Shares | 99↑20.2% | 82↑6.7% | 77↑10.2% | 70↑9.0% | 64 | |
| Weighted Average Diluted Shares | 99↑20.2% | 82↑6.7% | 77↑10.2% | 70↑9.0% | 64 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.